Company
Melbourne, VIC
Every investor coverage indicates participated in a round The Peter Doherty Institute for Infection and Immunity raised.
Companies The Peter Doherty Institute for Infection and Immunity acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| David Jackson | Professorial Fellow | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming The Peter Doherty Institute for Infection and Immunity. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The Victorian government granted Monash Institute of Pharmaceutical Sciences $5 million for mRNA vaccine manufacturing ahead of Phase 1 trials; the vaccine earlier attracted $3 million from the Medical Research Future Fund.
Year-end review of Australian additive manufacturing covering listings by AML3D and Amaero, capital raises at several firms, GoProto's acquisitions, defence sector engagements, and the author's own 2020 activities.
Biotech Immuron raised $28 million from US institutional investors after reporting its Travelan product showed antiviral activity against coronavirus in a laboratory study, and holds a US defence grant.